Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Soleno Therapeutics ( (SLNO) ).
On March 16, 2026, Soleno Therapeutics’ Board of Directors approved amended and restated bylaws, acting on recommendations from its Nominating and Corporate Governance Committee. The changes update advance notice requirements for shareholder proposals and director nominations, incorporate recent Delaware law developments, refine governance practices, add a forum selection clause, and make technical clarifications, signaling a tightening of the company’s corporate governance framework and shareholder engagement protocols.
These bylaw revisions could streamline how shareholder business is brought before the company, reduce legal uncertainty, and concentrate dispute resolution in specified courts. For investors and other stakeholders, the move suggests an effort to modernize Soleno’s governance structure, potentially improving predictability in corporate processes while also shaping how activist or dissident shareholders can interact with the company in future proxy seasons.
The most recent analyst rating on (SLNO) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.
Spark’s Take on SLNO Stock
According to Spark, TipRanks’ AI Analyst, SLNO is a Neutral.
The score is primarily supported by the 2025 financial inflection (new revenue scale, profitability, and positive free cash flow) and very strong balance sheet, reinforced by earnings-call evidence of accelerating commercial launch KPIs and substantial cash. Offsetting factors are weak technical momentum (below key moving averages and negative MACD) and limited valuation support given a negative P/E and no dividend yield.
To see Spark’s full report on SLNO stock, click here.
More about Soleno Therapeutics
Soleno Therapeutics operates in the biopharmaceutical industry, focusing on the development of therapies for rare diseases and other specialized medical conditions. The company targets niche patient populations where there are significant unmet medical needs and seeks to advance treatments through clinical development and regulatory pathways.
Average Trading Volume: 1,561,965
Technical Sentiment Signal: Sell
Current Market Cap: $1.74B
Find detailed analytics on SLNO stock on TipRanks’ Stock Analysis page.